For example, combining the ER antagonist fulvestrant with the CDK4/6 inhibitors palbociclib significantly improved outcomes in patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.